Nadrich & Cohen is actively representing patients who have developed severe hypocalcemia (very low levels of calcium in the blood) after taking the osteoporosis drug Prolia (denosumab).
If you have developed severe hypocalcemia after taking Prolia, you may be entitled to financial compensation for medical bills, lost wages, pain, suffering and more. If you have lost a loved one who died due to severe hypocalcemia after taking Prolia, we can file a wrongful death claim on your behalf seeking financial compensation.
Our Prolia attorneys have been representing victims of dangerous drugs since 1990. We have recovered in excess of $400,000,000 for our injured clients. We have vast experience in holding big pharma accountable for injuring victims of dangerous drugs.
We represent victims of dangerous medications like Prolia on a contingency fee basis. This means that we don’t charge dangerous drug victims any fee until and unless we recover money to compensate them for their injuries. This means that if we represent you and file a denosumab lawsuit on your behalf, we won’t charge you any upfront fees or out of pocket fees. The only fee you’ll ever owe us for us to handle your Prolia case is a percentage of any compensation we recover for you.
Call us today for a free consultation, fill out the free case evaluation form on this page or text us from this page if you or a loved one developed severe hypocalcemia after taking Prolia. You might qualify for financial compensation in a Prolia lawsuit.
Compensation Available In A Prolia Lawsuit
If you have developed hypocalcemia after being given Prolia, you may be eligible for financial compensation for:
You’re probably already facing huge medical bills if you developed hypocalcemia after being given Prolia. You may require future treatment due to your injuries as well, which will generate even more medical expenses. We can help you recover compensation for any past or future medical bills associated with your hypocalcemia.
If you missed time from work due to your hypocalcemia, whether it be because you were too sick to work or because you had to take time off from work to be treated, we can help you recover compensation for the wages you weren’t able to earn.
Loss Of Earning Capacity
If your hypocalcemia left you disabled and unable to work again or unable to do the work you used to again, we can help you recover compensation for the loss or reduction of your earning capacity this caused.
Pain And Suffering
Your hypocalcemia may have caused you to experience physical pain and mental suffering. We are experts at putting an accurate value on the pain and suffering that our dangerous drug clients endure and ensuring they are fairly compensated for it.
If you lost a loved one to Prolia-induced hypocalcemia, we can file a wrongful death lawsuit on your behalf seeking financial compensation for:
- Your loved one’s pain and suffering
- Your loved one’s medical bills
- Your loved one’s funeral and burial costs
- Your suffering and grieving
- The loss of your loved one’s consortium
- The loss of your loved one’s household services
- The loss of your loved one’s income
- The loss of your loved one’s love and companionship
Prolia And Hypocalcemia
On January 19, 2024, the FDA announced it was adding a Boxed Warning, its strongest warning, to Prolia’s label.
The Boxed Warning warns that Prolia has been linked with an increased risk of severe hypocalcemia in advanced chronic kidney disease patients, especially dialysis patients.
The FDA stated that the warning was based on the results of two studies, plus adverse events reports submitted to FAERS, the FDA Adverse Event Reporting System.
According to the FDA, one of the studies investigated 1,523 women on dialysis who were given Prolia and 1,281 women on dialysis who were given oral bisphosphonates. 41.1 percent of the women treated with Prolia developed severe hypocalcemia, compared to 2 percent of the women who were treated with oral bisphosphonates.
The other study, according to the FDA, investigated 495,269 women who were given Prolia, 899,311 women who were given oral bisphosphonates, and 212,430 women who were given intravenous bisphosphonates. The study found that the rate of severe hypocalcemia in the patients given Prolia was 218.9 per 100,000 person-years, compared to 52.1 per 100,000 person-years in the patients given intravenous bisphosphonates and 19.4 per 100,000 person-years in the patients given oral bisphosphonates. 8.7 percent of Prolia patients who developed severe hypocalcemia developed cardiac arrhythmias, with 3.3 of Prolia patients who developed severe hypocalcemia dying.
The FDA also mentioned 77 adverse event reports, submitted from July 2010 through May 2021, involving patients who developed severe hypocalcemia after receiving Prolia.
According to the FDA, these patients developed symptoms including:
- Face twitching
- Irregular heart rhythm
The FDA announcement came after the FDA announced in November 2022 that it was investigating the risk of severe hypocalcemia associated with dialysis patients taking Prolia.
Prolia Long Linked With Hypocalcemia
Prolia has long been linked with hypocalcemia in scientific literature. In fact, its link with hypocalcemia has been so thoroughly documented for so long that, by now, it is clear that Prolia as a medication is defective by design – it is unsafe when used as intended or in a reasonably foreseeable manner.
When drugs like Prolia are defective by design, their manufacturers are strictly liable for any injuries caused by the drugs. Those injured by defective drugs can recover compensation for their injuries by filing a lawsuit against the manufacturers of the drugs.
Denosumab has been linked with hypocalcemia by numerous scientific studies and case reports, including:
- A 2014 case report describes a metastatic prostate cancer patient who developed hypocalcemia after taking denosumab. The authors note that denosumab is linked with a “significantly increased risk” of hypocalcemia development.
- A 2014 case report describes a man who developed hypocalcemia after being given denosumab. The man’s hypocalcemia persisted for almost six months, requiring aggressive treatment.
- A 2016 study noted that numerous other studies have linked hypocalcemia with denosumab, and that hypocalcemia can lead to cardiac arrhythmia or death.
- A 2016 review article found that 9.6 percent of patients treated with denosumab developed hypocalcemia. The authors recommend that denosumab patients supplement with calcium and vitamin D while taking the medication.
- A 2016 case report described a man who developed hypocalcemia after taking denosumab. The authors recommend that denosumab patients have their calcium levels monitored and be co-administered calcium and vitamin D.
- A 2018 case report describes a man who developed hypocalcemia after being given denosumab. The authors note that it is “well-recognized” that hypocalcemia can develop after denosumab administration.
- A 2019 case report described a man who developed denosumab-induced hypocalcemia. While the hypocalcemia resolved in 14 days, the patient later returned with a second bout of hypocalcemia, which took much longer to resolve than the first.
- A 2019 case report described two patients who developed severe hypocalcemia after being given denosumab. The authors note that “hypocalcemia is not a rare adverse event following the administration of denosumab.”
- A 2019 case report described a man who presented to an emergency room with shoulder pain and was found to have hypocalcemia caused by denosumab. The authors recommend that all patients who are given denosumab should have their calcium levels monitored.
- A 2019 study found that 7.4 percent of patients who took denosumab developed hypocalcemia. The authors recommend that denosumab patients receive calcium and vitamin D supplementation, and advise that high-risk denosumab patients have their calcium levels monitored.
- A 2022 case report described a woman who developed hypocalcemia after taking denosumab. The authors note that denosumab is linked with an increased risk of hypocalcemia, and that a review of seven studies found that 5.2 percent of denosumab patients develop hypocalcemia.
- A 2023 study found that 23 percent of patients given denosumab developed hypocalcemia. The authors concluded that hypocalcemia associated with denosumab is “more prevalent than previously shown.”
- A 2023 study found that hypocalcemia occurred after 6.3 percent of denosumab injections. The authors described hypocalcemia as “a prevalent adverse event” in denosumab patients.
- A 2023 case report described a woman who suffered cardiac arrest when she developed hypocalcemia after taking denosumab.
Despite the long, well-documented link between Prolia and hypocalcemia, Amgen has continued to manufacture and sell this clearly dangerous, defective drug.
Nadrich & Cohen has been representing victims of defective drugs for over 30 years. Amgen has known for years that Prolia was defective yet continued to manufacture and sell it. Call us today for a free consultation so we can hold Amgen accountable for their actions and recover financial compensation on your behalf.
Experienced Dangerous Drug Lawyers
If it is your health which is at stake, choosing a lawyer to represent you against big pharma is an incredibly important decision. A law firm needs proven experience and extensive resources to take on an industry involving trillions of dollars while it navigates a complex dangerous drug case.
At Nadrich & Cohen, we have been helping victims of defective drugs and defective medical devices since 1990. By doing so, we have established ourselves as leaders in the defective drug legal space.
The philosophy at Nadrich & Cohen is impactful, yet simple: every client is treated like family. Our purpose will always be the same regardless of the size of your case: our purpose is to preserve your financial and physical well-being.
When you work with a dangerous drug lawyer at Nadrich & Cohen, you will receive:
- A reputation for success: The lawyers at Nadrich & Cohen have been recognized by numerous organizations for their success and quality legal representation, such as the Better Business Bureau, Lead Counsel, The National Trial Lawyers Top 100 Trial Lawyers and America’s Top 100 High Stakes Litigators. However, we receive the most satisfaction from the relationships that we have built with clients over the past 30+ years. We strive to provide each client with the personalized attention they deserve.
- Transparency and responsiveness: We know that you may be going through an uncertain and difficult time. It’s natural that you’re anxious to receive answers since your future is dependent upon a successful outcome. Whether it’s a case status update or a response to a question you had, we’ll always give you the answers you need so you can feel like you’re at ease.
- Relentless fight: This isn’t just our job – it’s our calling. We fight tooth and nail for our clients, dedicating countless hours to coming up with strategies which will obtain results for our clients. This is why we’ve recovered hundreds of millions of dollars for injury victims.
If you are searching for an experienced lawyer for your Prolia case, Nadrich & Cohen will fight for you and won’t stop until we win your case.
How Long Do I Have To File A Prolia Lawsuit?
There is a time limit to file a lawsuit if you have been injured by Prolia. This time limit is known as a statute of limitations and varies from state to state. For example, the time limit to file an injury lawsuit in California is typically two years from the date of the injury, although certain circumstances can alter this time limit.
We are familiar with the statutes of limitations in all states. Call us today for a free consultation if you’ve developed hypocalcemia after taking Prolia and are unsure as to how long you have to file a lawsuit.
If you’ve developed hypocalcemia after taking Prolia, you need experienced lawyers with a long track record of success to take on a pharmaceutical giant like Amgen, who reported over $26 billion in revenue in 2022.
Nadrich & Cohen has been representing injury victims against the pharmaceutical industry for over three decades, having recovered hundreds of millions of dollars on behalf of injury victims. We have the experience, know-how and resources to take on even the largest pharmaceutical giants.
Call us today for a free consultation if you or a loved one developed hypocalcemia after taking Prolia. You might be entitled to a financial recovery in a Prolia lawsuit against Amgen.